Zoster Treatment companies

Key Zoster Treatment Market Players:

The global zoster treatment is highly competitive, with players such as GSK and Merck & Co. commanding nearly 50.4% of zoster treatment market share, mainly due to Shingrix and Zostavax. Emerging rivalry is being pushed by generic antiviral companies in India and developing recombinant vaccination efforts in Asia-Pacific. Pfizer and BioNTech jointly collaborate on R&D in herpes mRNA vaccines, and government-specified production by SK Bioscience and Pharmaniaga are moving on a trend towards manufacturing autonomy.

Here is a list of key players operating in the global zoster treatment market:

Company Name	Country of Origin	Industry Focus	Estimated Market Share (2037)
GSK plc	United Kingdom	Developer of Shingrix, a recombinant zoster vaccine; dominates global market	31.7%
Merck & Co., Inc.	U.S.	Developer of Zostavax; focuses on vaccine innovation and adult immunization	19.2%
Sanofi S.A.	France	Focused on antiviral drugs; expanding presence in elder care therapeutics	7.6%
Pfizer Inc.	U.S.	Investment in herpes zoster pipeline and combination therapies	6.9%
Daiichi Sankyo Co., Ltd.	Japan	Japanese firm with strong domestic distribution of zoster antivirals	4.5%
Takeda Pharmaceutical Co. Ltd.	Japan	Focus on long-acting antivirals and vaccine co-development	xx%
BioNTech SE	Germany	R&D in herpesvirus mRNA vaccines and collaborative trials	xx%
SK Bioscience Co., Ltd.	South Korea	Regional player with recombinant vaccine development for Zoster	xx%
Aurobindo Pharma Ltd.	India	Leading supplier of generic acyclovir and valacyclovir	xx%
Sun Pharmaceutical Industries	India	Manufacturing oral antivirals; expanding government contracts in Asia	xx%
CSL Limited	Australia	Active in vaccine formulations and biopharma partnerships	xx%
Moderna, Inc.	U.S.	Exploring mRNA herpesvirus platforms under clinical development	xx%
Abbott Laboratories	U.S.	Focus on rapid diagnostic tools and chronic management platforms	xx%
Zydus Lifesciences Ltd.	India	Generic antiviral developer; government supplier in low-cost markets	xx%
Serum Institute of India	India	Entering herpes zoster space with affordable vaccine R&D	xx%
Hikma Pharmaceuticals	UK/Jordan	Manufacturing antivirals; targeting hospital-based markets	xx%
Green Cross Corp.	South Korea	Local vaccine R&D player; supported by national initiatives	xx%
Pharmaniaga Berhad	Malaysia	Malaysian state-linked company producing antivirals and hospital generics	xx%
Novartis AG	Switzerland	Diversified focus; participating in collaborative zoster research	xx%
Dr. Reddy’s Laboratories	India	Major API and finished dosage exporter for acyclovir and valacyclovir	xx%

Below are the areas covered for each company in the zoster treatment market:

• Company Overview
• Business Strategy
• Key Product Offerings
• Financial Performance
• Key Performance Indicators
• Risk Analysis
• Recent Development
• Regional Presence
• SWOT Analysis